Awardee OrganizationUNIVERSITY OF CALIFORNIA LOS ANGELES
Description
Abstract Text
Description: The UCLA Transgenic Mouse/Embryonic Stem (ES) Cell Shared
Resource was established to accommodate individual investigator?s needs in the
production of transgenic and knockout mice and to provide for rederivation of
strains to create specific pathogen-free mice. Resource personnel serve as
consultants to many different investigations providing information on specific
transgenic animal models, the design and assembly of DNA constructs, and the
development of new methods. Materials can also be provided to investigators
who wish to perform projects in their own laboratories. There are two
separate components of the resource: Transgenic Mouse and ES Cell Culture.
The Transgenic Mouse Facility was established in 1991. Although not funded by
NCI in the last competitive renewal application, the institution has
subsidized the facility?s operation because access to transgenic and knockout
technology plays a vital role in the Cancer Center?s research mission. The
facility performs pronuclear injections of DNA and blastocyst injections of
targeted ES cells, rederives mouse strains, and maintains transgenic animal
lines in their initial stages.
The Embryonic Stem Cell Facility is not yet operational. Institutional funds
have been utilized to recruit a director, renovate space, and provide
equipment for the facility. Once operational, a formal service for culture,
electroporation, drug selection, and expansion of ES clones will be available.
The measure of usage is based on injection days for the transgenic facility
and targeting projects for the ES facility. The total capacity for the
transgenic facility is 240 injection days and for the ES facility, 25 cell
targeting projects. Twenty four UCLA faculty members used the resource
representing assistance to 66 individual projects. Of these, use by peerreviewed
Cancer Center members totaled 60 percent. The total operating budget
of the shared resource for 1997-1998 is $259,672, with 25 percent requested,
50 percent to be obtained from AIDS chargebacks, and 25 percent from
institutional support.
No Sub Projects information available for 5P30CA016042-28 9021
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5P30CA016042-28 9021
Patents
No Patents information available for 5P30CA016042-28 9021
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5P30CA016042-28 9021
Clinical Studies
No Clinical Studies information available for 5P30CA016042-28 9021
News and More
Related News Releases
No news release information available for 5P30CA016042-28 9021
History
No Historical information available for 5P30CA016042-28 9021
Similar Projects
No Similar Projects information available for 5P30CA016042-28 9021